Search results for "neoplasms"

showing 10 items of 7988 documents

Controversies in ameloblastoma management: Evaluation of decision making, based on a retrospective analysis

2020

Background The ameloblastoma management is still challenging to the high recurrence rates and significant morbidity associated with radical treatment. The purpose of this 10-year retrospective study was to analyze the influence of ameloblastoma type and treatment strategy on the long-term outcomes and recurrence rates. Material and Methods The retrospective analyses of 64 histologically-confirmed ameloblastoma cases was performed. The possible risk factors for recurrence and the development of complications were estimated statistically. Results The treatment strategy applied for this group of patients was the following: thirty-four patients (53.1%) were treated conservatively with enucleati…

primary stabilitymedicine.medical_specialtymedicine.medical_treatmentsecondary stabilityDecision MakingEnucleationundersized drillingEsthetics DentalInferior alveolar nerveAmeloblastoma03 medical and health sciences0302 clinical medicineSDG 3 - Good Health and Well-beingOral and maxillofacial pathologymedicineHumansAmeloblastomaGeneral DentistryUNESCO:CIENCIAS MÉDICASRetrospective StudiesParesisrfaOral Medicine and Pathologybusiness.industryResearchRetrospective cohort study030206 dentistrymedicine.diseaseimmediate implantsCurettageSurgeryMandibular NeoplasmsOtorhinolaryngologyQuality of Life/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_beingSurgeryNeoplasm Recurrence Localmedicine.symptombusinessComplicationinsertion torque
researchProduct

Lifestyle and Empowerment Techniques in Survivorship of Gynaecologic Oncology (LETSGO study): A study protocol for a multicentre longitudinal interve…

2021

IntroductionThe number of gynaecological cancer survivors is increasing and there is a need for a more sustainable model of follow-up care. Today’s follow-up model is time-consuming and patients have reported unmet needs regarding information about their cancer and strategies for managing the consequences of treatment. The main aim of this study is to assess health-related empowerment—in terms of patient education, psychosocial support, and promotion of physical activity—in a new follow-up model by comparing it to standard follow-up in a quasi-randomised study involving intervention hospitals and control hospitals.Methods and analysisAt the intervention hospitals, patients will be stratifie…

protocols & guidelinesSurvivorship0302 clinical medicineinformation technologyHealth careMulticenter Studies as Topichealth economics030212 general & internal medicine1506Empowermentmedia_commonBiological Specimen BanksRandomized Controlled Trials as TopicRHealth technologyPublic Health Global Health Social Medicine and EpidemiologyGeneral MedicineBiobankOncologyVDP::Medisinske Fag: 700::Helsefag: 800030220 oncology & carcinogenesisCancer treatmentMedicineFemale1717Hälso- och sjukvårdsorganisation hälsopolitik och hälsoekonomimedicine.medical_specialtyGenital Neoplasms Femalemedia_common.quotation_subjectHealth-related empowermentBiomedical Technologyquality in health care03 medical and health sciencesQuality of life (healthcare)medicineHumansLife StyleConsequencesGynaecological cancerHealth economicsbusiness.industryVDP::Medical disciplines: 700::Clinical medical disciplines: 750::Oncology: 762gynaecological oncologychange managementRepeated measures designHealth Care Service and Management Health Policy and Services and Health EconomyVDP::Medisinske Fag: 700::Klinisk medisinske fag: 750::Onkologi: 762Folkhälsovetenskap global hälsa socialmedicin och epidemiologiFamily medicineQuality of LifeFollow-up careNeoplasm Recurrence LocalbusinessPatient education
researchProduct

Predictors of health-related quality of life in Serbian patients with head and neck cancer.

2021

The aim of this study was to identify predictors of the Health-Related Quality of Life (HRQoL) in patients with head and neck cancers (HNCs). In total, 345 patients with HNCs were interviewed. A self-report questionnaire was administered to collect data about demographic characteristics, health status, smoking, alcohol consumption habits, and HRQoL. It were used the EORTC Instruments - Quality of Life Questionnaire-Core 30-questions (QLQ-C30), Quality of Life Questionnaire - Head and Neck Module 35-questions (QLQ-H&N 35) and OHIP-14 instrument for HRQoL assessments. Clinical information and treatment data were collected from medical records. Five groups of HRQoL predictors were identified: …

quality of life (qol)orthognathic surgeryHealth Statusorthognathic quality of lifedentofacial deformityOtorhinolaryngologyHead and Neck NeoplasmsSurveys and QuestionnairesQuality of LifeHumansSurgeryGeneral DentistrySerbiaUNESCO:CIENCIAS MÉDICASMedicina oral, patologia oral y cirugia bucal
researchProduct

Aplidin® induces JNK-dependent apoptosis in human breast cancer cells via alteration of glutathione homeostasis, Rac1 GTPase activation, and MKP-1 ph…

2006

Aplidin® is an antitumor agent in phase II clinical trials that induces apoptosis through the sustained activation of Jun N-terminal kinase (JNK). We report that Aplidin® alters glutathione homeostasis increasing the ratio of oxidized to reduced forms (GSSG/GSH). Aplidin® generates reactive oxygen species and disrupts the mitochondrial membrane potential. Exogenous GSH inhibits these effects and also JNK activation and cell death. We found two mechanisms by which Aplidin® activates JNK: rapid activation of Rac1 small GTPase and downregulation of MKP-1 phosphatase. Rac1 activation was diminished by GSH and enhanced by L-buthionine (SR)-sulfoximine, which inhibits GSH synthesis. Downregulatio…

rac1 GTP-Binding ProteinProgrammed cell deathSmall interfering RNAGlutathione reductaseDown-RegulationAntineoplastic AgentsApoptosisBreast NeoplasmsCell Cycle ProteinsBiologyPeptides CyclicImmediate-Early ProteinsMembrane Potentialschemistry.chemical_compoundMiceDownregulation and upregulationDepsipeptidesProtein Phosphatase 1Phosphoprotein PhosphatasesAnimalsHomeostasisHumansMolecular Biologychemistry.chemical_classificationReactive oxygen speciesGlutathione PeroxidaseGlutathione DisulfideJNK Mitogen-Activated Protein KinasesProtein phosphatase 1Dual Specificity Phosphatase 1Cell BiologyGlutathioneCell biologyEnzyme ActivationOxidative StressGlutathione ReductasechemistryMitochondrial MembranesGlutathione disulfideCalciumProtein Tyrosine PhosphatasesReactive Oxygen SpeciesCopperHeLa CellsCell Death and Differentiation
researchProduct

Rho GTPases in human breast tumours: expression and mutation analyses and correlation with clinical parameters

2002

In the present study, we addressed the question of a putative relevance of Rho proteins in tumour progression by analysing their expression on protein and mRNA level in breast tumours. We show that the level of RhoA, RhoB, Rac1 and Cdc42 protein is largely enhanced in all tumour samples analysed (n=15) as compared to normal tissues originating from the same individual. The same is true for 32P-ADP-ribosylation of Rho proteins which is catalysed by Clostridium botulinum exoenzyme C3. Also the amount of Rho-GDI and ERK2 as well as the level of overall 32P-GTP binding acvitity was tumour-specific elevated, yet to a lower extent than Rho proteins. Although the amount of Rho proteins was enhance…

rac1 GTP-Binding Proteinrho GTP-Binding ProteinsCancer ResearchRHOAProliferation indexRHOBBlotting WesternDNA Mutational AnalysisRhoCGene ExpressionBreast NeoplasmsRAC1breast tumoursCDC42Polymerase Chain ReactionRho GTPasesRhoB GTP-Binding ProteinHumansBreastRNA Messengercdc42 GTP-Binding ProteinrhoB GTP-Binding Proteinmutation analysisADP Ribose TransferasesMitogen-Activated Protein Kinase 1biologyGenetics and GenomicsMolecular biologyOncologyCdc42 GTP-Binding ProteinMutationtumour progressionDisease Progressionbiology.proteinFemaleGuanosine TriphosphaterhoA GTP-Binding ProteinBritish Journal of Cancer
researchProduct

Rac1 protein signaling is required for DNA damage response stimulated by topoisomerase II poisons.

2012

To investigate the potency of the topoisomerase II (topo II) poisons doxorubicin and etoposide to stimulate the DNA damage response (DDR), S139 phosphorylation of histone H2AX (γH2AX) was analyzed using rat cardiomyoblast cells (H9c2). Etoposide caused a dose-dependent increase in the γH2AX level as shown by Western blotting. By contrast, the doxorubicin response was bell-shaped with high doses failing to increase H2AX phosphorylation. Identical results were obtained by immunohistochemical analysis of γH2AX focus formation, comet assay-based DNA strand break analysis, and measuring the formation of the topo II-DNA cleavable complex. At low dose, doxorubicin activated ataxia telangiectasia m…

rac1 GTP-Binding Proteinrho GTP-Binding ProteinsDNA damageAntineoplastic AgentsBiochemistryPoisonsCell LineHistonesNeoplasmsmedicineAnimalsTopoisomerase II InhibitorsDoxorubicinMolecular BiologyEtoposidebiologyCell DeathTopoisomeraseCell BiologyMolecular biologyImmunohistochemistryRatsComet assayHistoneDNA Topoisomerases Type IIDNA Topoisomerases Type Ibiology.proteinPhosphorylationTopoisomerase-II InhibitorHydroxymethylglutaryl-CoA Reductase Inhibitorsmedicine.drugDNA DamageSignal TransductionThe Journal of biological chemistry
researchProduct

Value of Combined PET Imaging with [18F]FDG and [68Ga]Ga-PSMA-11 in mCRPC Patients with Worsening Disease during [177Lu]Lu-PSMA-617 RLT

2021

Despite the promising results of prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) in metastatic castration-resistant prostate cancer (mCRPC), some patients show worsening disease during PSMA-RLT. We investigated the value of combined [18F]FDG and [68Ga]Ga-PSMA-11 PET imaging in this setting. In n = 29 mCRPC patients with worsening disease after a median of four cycles of [177Lu]Lu-PSMA-617 RLT, combined [18F]FDG and [68Ga]Ga-PSMA-11 PET imaging was performed to detect [18F]FDG-avid lesions with low or no PSMA expression (mismatch lesions). To evaluate prognostic implication of mismatch, survival analyses regarding presence, location, and [18F]FDG PET-derived para…

radioligand therapy; PSMA; FDG; PET/CT; mismatch; metastatic castration-resistant prostate cancerCancer Researchmedicine.medical_specialtyFDGPET/CTUrology610Diseaseurologic and male genital diseasesMetastasisProstate cancerPSMAmedicineRC254-282Membrane antigenPET-CTbusiness.industryNeoplasms. Tumors. Oncology. Including cancer and carcinogensPet imagingMetabolic tumor volumemedicine.diseaseradioligand therapyTotal lesion glycolysismetastatic castration-resistant prostate cancerOncologybusinessmismatchCancers
researchProduct

Structured reporting of rectal cancer staging and restaging: A consensus proposal

2021

Background: Structured reporting (SR) in oncologic imaging is becoming necessary and has recently been recognized by major scientific societies. The aim of this study was to build MRI-based structured reports for rectal cancer (RC) staging and restaging in order to provide clinicians all critical tumor information. Materials and Methods: A panel of radiologist experts in abdominal imaging, called the members of the Italian Society of Medical and Interventional Radiology, was established. The modified Delphi process was used to build the SR and to assess the level of agreement in all sections. The Cronbach’s alpha (Cα) correlation coefficient was used to assess the internal consistency of ea…

re-stagingCancer Researchmedicine.medical_specialtyStagingColorectal cancerIntraclass correlationModified delphiArticle030218 nuclear medicine & medical imaging03 medical and health sciencesRe‐staging0302 clinical medicineMagnetic resonance imagingmagnetic resonance imaging; rectal cancer; re‐staging; staging; structured reportingCronbach's alphaStructured reportingInternal consistencymedicineMedical physicsRectal cancerRC254-282Final versionmedicine.diagnostic_testbusiness.industryNeoplasms. Tumors. Oncology. Including cancer and carcinogensInterventional radiologymedicine.diseaseOncology030220 oncology & carcinogenesisbusinessStructured reporting
researchProduct

Oxidative and nitrosative stress in the metastatic microenvironment.

2010

Metastases that are resistant to conventional therapies are the main cause of most cancer-related deaths in humans. Tumor cell heterogeneity, which associates with genomic and phenotypic instability, represents a major problem for cancer therapy. Additional factors, such as the attack of immune cells or organ-specific microenvironments, also influence metastatic cell behavior and the response to therapy. Interaction of cancer and endothelial cells in capillary beds, involving mechanical contact and transient adhesion, is a critical step in the initiation of metastasis. This interaction initiates a cascade of activation pathways that involves cytokines, growth factors, bioactive lipids and r…

reactive oxygen speciesCancer ResearchTumor microenvironmentCancerReviewBiologylcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaselcsh:RC254-282Primary tumorMetastasischemistry.chemical_compoundImmune systemreactive nitrogen speciesOncologychemistryImmunologyCancer cellmedicineCancer researchCytotoxic T celltumor microenvironmentmetastasesReactive nitrogen speciesCancers
researchProduct

Kinetics of Renal Function during Induction in Newly Diagnosed Multiple Myeloma: Results of Two Prospective Studies by the German Myeloma Study Group…

2021

Background: Preservation of kidney function in newly diagnosed (ND) multiple myeloma (MM) helps to prevent excess toxicity. Patients (pts) from two prospective trials were analyzed, provided postinduction (PInd) restaging was performed. Pts received three cycles with bortezomib (btz), cyclophosphamide, and dexamethasone (dex

renal failurekidneyendocrine systemCancer Researchmedicine.medical_specialtyCyclophosphamide030232 urology & nephrologyUrologyRenal functionlcsh:RC254-282NiereninsuffizienzArticleBortezomib03 medical and health sciences0302 clinical medicineMultiple myelomamedicineddc:610Renal insufficiencyLenalidomideDexamethasoneMultiple myelomaLenalidomideKidneybusiness.industryBortezomiblcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensinduction regimenmedicine.disease3. Good healthmedicine.anatomical_structureOncology030220 oncology & carcinogenesisPlasmozytombusinessDDC 610 / Medicine & healthKidney diseasemedicine.drugCancers
researchProduct